IFNA1 and myeloid sarcoma: Compared with a study investigating treatment patterns in MS in the US during 2001–2010, similar patterns were observed in most MS patients who were users of IFN β-1a and IFN β-1b; however, they tended to transfer to the use of IFN, GA or natalizumab rather than to fingolimod26.